<DOC>
	<DOC>NCT01626573</DOC>
	<brief_summary>This is a study evaluating a 28-day course followed by a 56-day course of INCB039110 in patients with active rheumatoid arthritis (RA). The study will evaluate safety and efficacy parameters of INCB039110.</brief_summary>
	<brief_title>A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Subjects with active RA aged 18 to 75 years of age and meet tender and swollen joint assessment expectations defined in the study protocol. cReactive protein (CRP) or erythrocyte sedimentation rate (ESR) laboratory values meet minimal study protocol expectations. Females who are pregnant or breastfeeding. Men and women who cannot comply with requirements to avoid fathering a child or becoming pregnant, respectively. Subjects treated with a biologic agent within 12 weeks prior to first dose of study drug. (12 months in the case of rituximab.) Subjects with a history or currently suspected inflammatory disease other than RA. Subjects with a history of hematological disorders.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>RA</keyword>
	<keyword>Active</keyword>
</DOC>